Investment Rating - The investment rating for Tianli International Holdings (01773.HK) is "Outperform the Market" (maintained) [2][16]. Core Views - The company is strategically expanding its enrollment of transfer students to counteract the previous slowdown in enrollment growth, with a target of approximately 7,000 transfer students for the fiscal year 2026, which is expected to increase the total number of students served by about 14% year-on-year [3][5]. - The effectiveness of the AI education products is being continuously validated, leading to accelerated revenue conversion. The AI Sprint Camp has reached 1,934 students, with expectations to exceed 4,000 students for the fiscal year 2026, generating projected revenues of CNY 88 million [3][8][11]. - Revenue forecasts for FY2026 to FY2028 are projected at CNY 39.15 billion, CNY 42.25 billion, and CNY 44.99 billion, respectively, with corresponding growth rates of 9.1%, 7.9%, and 6.5% [3][16]. Summary by Sections Enrollment Strategy - The company is actively adjusting its enrollment strategy to address the short-term negative impact on enrollment growth. As of January 25, 2026, 3,603 transfer students have been enrolled, with a projected total of 14.8 million students served in FY2026, reflecting a year-on-year increase of approximately 14% [3][5]. - The strategy includes a slight relaxation of enrollment standards to increase student reserves while maintaining teaching quality [7]. AI Education Business - The AI Sprint Camp business is accelerating its commercialization, with expected revenue conversion of CNY 88 million for FY2026. The program has shown significant improvement in student performance, with an average score increase of 48 points for nearly 1,000 students in the latest pilot [8][10]. - The AI education system, developed by the company's subsidiary, aims to provide additional educational resources to students who are lagging behind, thereby enhancing overall school performance and reputation [10][11]. Share Buyback and Investor Confidence - The company announced a share buyback plan, intending to repurchase up to CNY 200 million worth of shares in the open market, which is expected to enhance investor confidence [3][12].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 239.40 [2][9][12] Core Insights - The company reported a revenue of RMB 7.759 billion for 2025, a slight decrease of 2.4% year-over-year, which was below Bloomberg's expectation of RMB 7.9 billion. However, the adjusted net profit was RMB 2.86 billion, reflecting a significant year-over-year increase of 68.2% [6][8] - The company plans to increase customer acquisition efforts in 2026, focusing on expanding its paid user base and improving gross margins through enhanced operational efficiency [6][7] - The adjusted net profit forecast for 2026 and 2027 has been revised down to RMB 22.39 billion and RMB 25.20 billion, respectively, reflecting a 16% reduction in expectations [9][12] Financial Performance Summary - Revenue projections for the upcoming years are as follows: RMB 8.619 billion in 2026, RMB 9.339 billion in 2027, and RMB 10.038 billion in 2028, with growth rates of 11.08%, 8.35%, and 7.48% respectively [5][12] - The adjusted net profit for 2026 is projected at RMB 2.239 billion, with an adjusted EPS of RMB 10.27, and a PE ratio of 20.71x [12][14] - The company’s gross margin improved by 2 percentage points to 35.7% in 2025, attributed to a decrease in revenue sharing costs and effective content licensing cost control [8][9] Market Position and Strategy - The company is focusing on the younger demographic passionate about music, aiming to expand its membership base through increased marketing and content production investments [7][9] - The report indicates that the company will continue to optimize promotional expenses, which decreased by 43% year-over-year, contributing to a 33.2% reduction in overall sales expenses [8][9]

证券研究报告 | 2026年02月10日 2026年02月11日 中芯国际（00981.HK） 优于大市 四季度收入超指引上限，预计 2026 年增速高于可比同业均值 4Q25 营收超指引上限，预计 2026 年收入增幅高于可比同业均值。公司 4Q25 实现销售收入 24.89 亿美元（YoY +12.8%，QoQ +4.5%），高于指引(QoQ 0%-2%) 上限，续创季度收入新高，晶圆收入占总收入的 92.4%；毛利率因折旧增加 降至 19.2%(YoY -3.4pct，QoQ -2.7pct)，符合指引；归母净利润为 1.73 亿 美元(YoY +60.7%，QoQ -10.0%)。预计 1Q26 营收环比持平，毛利率为 18%-20%， 2026 年全年收入增幅高于可比同业平均值。 四季度产能利用率环比基本持平，预计 2026 年资本开支与 2025 年持平。公 司 4Q25 付运折合 8 英寸晶圆 251 万片(YoY +26.3%，QoQ +0.6%)，产能利用 率为 95.7%(YoY +10.2pct，QoQ -0.1pct)。在晶圆收入中 12 英寸晶圆贡献 77.2%，8 英寸晶圆贡献 2 ...

Investment Rating - The report maintains a "Buy" rating for China Resources Vientiane Life (01209.HK) [1] Core Insights - The company has a solid competitive barrier in commercial management, combining certainty and flexibility in its operations. It leverages its brand resources and operational advantages to maintain resilience and profit elasticity amid industry competition [2] - The shopping center business leads the industry with high gross margins, driving profit elasticity. The company’s shopping centers achieved a retail sales growth of 21.1% year-on-year in the first half of 2025, with a gross margin of 78.7% [3] - The property management segment shows steady growth, with diversified operations expanding. The property management revenue in the first half of 2025 was 5.156 billion yuan, a year-on-year increase of 1.1% [4] - The company has ample cash flow and actively distributes dividends, maintaining a 100% payout ratio of core net profit since 2023. The quality of accounts receivable is also strong, with a net operating cash flow of 1.303 billion yuan in the first half of 2025 [5] - The company’s operational capabilities are industry-leading, with expected net profits for 2025-2027 at 39.03 billion, 43.31 billion, and 48.21 billion yuan, respectively, corresponding to price-to-earnings ratios of 25.0, 22.5, and 20.2 times [5] Summary by Sections 1. Commercial Operations and Property Management - The company has been deeply engaged in the property management sector for over 30 years, continuously enhancing its commercial and property management business systems. It operates shopping centers and office buildings, providing a comprehensive service system [17] - Revenue from the commercial segment has shown steady growth, with a compound annual growth rate (CAGR) of 25.9% from 2020 to 2024. The gross margin has improved from 27.0% in 2020 to 37.1% in the first half of 2025 [26] 2. Shopping Center Performance - The company’s shopping center business outperformed the industry, with a retail sales growth of 21.1% year-on-year in the first half of 2025. The rental income also increased by 17.2% year-on-year, with an occupancy rate of 97.1% [43] - The company has 125 shopping centers under management, with 53 projects ranking first in local market retail sales. The brand aggregation effect and customer traffic absorption capability continue to strengthen [43] 3. Property Management Growth - The property management segment provides a stable revenue base, with the urban space business contributing to growth. The revenue from urban space reached 949 million yuan in the first half of 2025, a year-on-year increase of 15.1% [4] - The company’s property management services have shown resilience, with a gross margin of 16.6% in the first half of 2025, benefiting from service structure optimization [4] 4. Financial Health and Dividends - The company maintains a strong cash flow position, with a net operating cash flow of 1.303 billion yuan in the first half of 2025 and cash and deposits totaling 17.921 billion yuan [5] - The company has consistently maintained a high dividend payout ratio, enhancing shareholder returns [5]

Investment Rating - The report gives a "Buy" rating for the company, indicating a positive outlook for its stock performance [3][6]. Core Insights - The company, Kingboard Laminates (1888.HK), is a leading manufacturer of copper-clad laminates with a vertically integrated supply chain, maintaining a global market share of 14.4% in 2024, the highest in the industry [2][3]. - The demand for copper-clad laminates is expected to grow due to the robust expansion of the PCB industry, driven by applications in AI servers, consumer electronics, automotive electronics, and communication devices [1][41]. - The company is well-positioned to benefit from rising copper prices and a tight supply environment, which are expected to enhance both pricing and profitability [2][3]. Company Overview - Kingboard Laminates was established in 1988 and has evolved into a major player in the copper-clad laminate market, with over 60 factories globally and a strong presence in South China and East China [1][16]. - The company specializes in various types of copper-clad laminates, including FR-4 epoxy glass fiber laminates, which are crucial for mainstream markets such as computers and communications [2][25]. Market Position - The copper-clad laminate market is characterized by high concentration, with the top four manufacturers holding approximately 50% of the market share, indicating significant barriers to entry and strong pricing power for established players [2][70]. - The report highlights that the company has a strong bargaining power due to its diversified customer base, with the top five customers accounting for less than 30% of total sales [2][3]. Financial Projections - The company is projected to achieve net profits of HKD 2.17 billion, HKD 3.95 billion, and HKD 4.84 billion for the years 2025, 2026, and 2027, respectively, reflecting growth rates of 64%, 82%, and 22% [3][5]. - The report indicates that the company's stock is currently undervalued compared to its peers, with projected P/E ratios of 27x, 15x, and 12x for the years 2025 to 2027 [3][5]. Industry Analysis - The PCB industry is expected to see a compound annual growth rate (CAGR) of 5.2% from 2024 to 2029, with the total market value projected to reach USD 94.66 billion by 2029 [1][44]. - The demand for high-frequency and high-speed copper-clad laminates is increasing, particularly in the AI server sector, which requires advanced materials to support higher data transmission rates [2][67].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2]. Core Insights - The report highlights the growth of the instant delivery sector, driven by the rise of e-commerce platforms and the increasing acceptance of instant retail among consumers. The company is positioned as the largest third-party instant delivery platform in China, having crossed the breakeven point and entered a new growth phase [7][12]. - The company has shown steady revenue growth since its establishment, with a projected revenue CAGR of approximately 34.3% from 2020 to 2024. In the first half of 2025, the company achieved a revenue of 10.236 billion yuan, representing a year-on-year increase of 48.81% [39][7]. - The report anticipates significant revenue growth for the company, projecting revenues of 21.973 billion yuan, 33.956 billion yuan, and 40.901 billion yuan for 2025, 2026, and 2027, respectively, with corresponding year-on-year growth rates of 39.54%, 54.54%, and 20.45% [83][82]. Business Development - The company has two main business segments: same-city delivery and last-mile delivery. The same-city delivery segment is benefiting from the growth of the instant retail industry, with a notable increase in revenue from business-to-business (B2B) services [27][21]. - In the first half of 2025, the B2B same-city delivery business generated revenue of 4.467 billion yuan, a year-on-year increase of 55.4%, while the business-to-consumer (B2C) segment generated 1.312 billion yuan, up 12.7% year-on-year [27][26]. - The last-mile delivery segment also saw significant growth, with revenue reaching 4.457 billion yuan in the first half of 2025, reflecting a year-on-year increase of 56.9% [31]. Industry Outlook - The instant retail industry is expected to accelerate, with the non-food delivery market projected to grow at a rate of approximately 27.7% in 2026, while the food delivery market is expected to grow at 5.9% [49][49]. - The report emphasizes the importance of logistics infrastructure and rider capacity as critical strategic resources for expansion in the instant delivery sector, with an expected CAGR of 17% for the industry from 2025 to 2028 [55][55]. Financial Projections - The company is expected to achieve a net profit of 2.38 billion yuan, 4.52 billion yuan, and 6.87 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 79.98%, 89.54%, and 51.95% [83][82]. - The report projects adjusted net profits of 3.76 billion yuan, 5.05 billion yuan, and 7.55 billion yuan for the same years, indicating strong profitability growth [83][82].

Investment Rating - The report maintains an "Outperform" rating for the company [6][3]. Core Insights - The company reported a revenue of $2.489 billion in Q4 2025, exceeding guidance and achieving a year-over-year growth of 12.8% [1]. - The gross margin decreased to 19.2% due to increased depreciation, which aligns with guidance [1]. - The company expects revenue growth in 2026 to surpass the average growth of comparable peers [1]. - The company plans to acquire 49% of the minority stake in SMIC North and increase its stake in SMIC South from 38.515% to 41.561% [3]. - The revenue from the industrial and automotive sectors grew significantly, with year-over-year increases of 81.4% and 43.4%, respectively [2]. Financial Performance - Q4 2025 sales revenue reached $2.489 billion, with wafer revenue accounting for 92.4% of total revenue [1]. - The company shipped 2.51 million 8-inch wafers in Q4 2025, a year-over-year increase of 26.3% [1]. - Capital expenditures for Q4 2025 were $2.408 billion, a 45% increase year-over-year [1]. - The company expects capital expenditures in 2026 to remain approximately the same as in 2025, around $8.1 billion [1]. Revenue and Profit Forecast - The company forecasts revenues of $9.327 billion, $11.008 billion, and $12.532 billion for 2025, 2026, and 2027, respectively, with growth rates of 16.2%, 18.0%, and 13.8% [5]. - Net profit estimates for 2025, 2026, and 2027 are $685 million, $876 million, and $1.031 billion, respectively, reflecting growth rates of 39.1%, 27.8%, and 17.7% [5].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 105.00, indicating a potential upside of 17.1% from the current price of HKD 89.65 [1][9]. Core Insights - The company has successfully secured a strategic partnership with Eli Lilly, marking its seventh collaboration and validating its antibody technology platform. This partnership is expected to significantly enhance the company's overseas development of early-stage assets and increase global commercialization certainty [2][7]. - The company anticipates strong commercial growth driven by its comprehensive pipeline in 2026, with projected product revenue growth of approximately 45% year-on-year to RMB 12.505 billion in 2025. Key products are expected to continue providing stable support for revenue growth [7][12]. - The management expects that three key assets, IBI363, IBI343, and IBI324, will enter global Phase III clinical trials, with IBI363 alone projected to contribute over USD 40 billion to the market [7][12]. Financial Forecast Changes - Revenue projections for 2025 have been revised down to RMB 12.505 billion, a decrease of 37.1% from previous estimates, while 2026 revenue is expected to rise to RMB 18.450 billion, an increase of 26.7% [3]. - Gross profit for 2025 is now forecasted at RMB 10.713 billion, down 41.0%, with a gross margin of 85.7%. For 2026, gross profit is expected to increase to RMB 16.064 billion, with a gross margin of 87.1% [3]. - The net profit forecast for 2025 has been significantly reduced to RMB 1.055 billion, a decrease of 87.9%, while 2026 net profit is projected to rise to RMB 3.502 billion, reflecting a 37.8% increase [3]. Stock Performance - The stock has shown a year-to-date increase of 17.57%, with a 52-week high of HKD 107.00 and a low of HKD 35.50, indicating strong market interest [6][11]. Valuation Model - The DCF valuation model estimates the equity value at RMB 161.238 million, translating to a per-share value of HKD 105.00, based on projected free cash flows and a WACC of 9.9% [8][15].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a potential upside in the stock price [6][12]. Core Insights - The company has achieved global sales exceeding 400 million units, with the "THE MONSTERS" series alone accounting for over 100 million units sold [7]. - The company is expected to experience significant revenue growth in 2025, with projected revenues between RMB 35.6 billion and RMB 43.6 billion, representing a year-on-year increase of 173% to 234% [12]. - New product launches in late 2025 and early 2026 have generated positive market responses, with some products showing a premium of approximately 48% [12]. - The company is strengthening its long-term development foundation by expanding its membership base to over 100 million and increasing its global store count to over 700 [12]. - The company is exploring new business avenues, including jewelry, desserts, theme parks, clothing, and film [12]. - Profit forecasts for 2025 to 2027 are optimistic, with expected net profits of RMB 12.26 billion, RMB 17.8 billion, and RMB 24.6 billion, respectively, indicating substantial growth rates [12]. Financial Summary - The company reported a net profit of RMB 476 million in 2022, with projections of RMB 1.08 billion in 2023 and RMB 3.13 billion in 2024, reflecting a significant recovery and growth trajectory [10]. - Earnings per share (EPS) are expected to rise from RMB 0.35 in 2022 to RMB 9.13 in 2025, showcasing a strong growth potential [10]. - The price-to-earnings (P/E) ratio is projected to decrease from 685 in 2022 to 26 in 2025, indicating an attractive valuation as earnings grow [10].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 105.00, indicating a potential upside of 17.1% from the current price of HKD 89.65 [1][9]. Core Insights - The company has successfully secured a strategic collaboration with Eli Lilly, marking its seventh major partnership and validating its antibody technology platform. This collaboration is expected to significantly enhance the company's overseas development of early-stage assets and increase global commercialization certainty [2][7]. - The company anticipates strong commercial growth driven by its oncology and comprehensive pipeline in 2026, with projected product revenue growth of approximately 45% year-on-year to RMB 12.505 billion in 2025. Key products are expected to continue supporting revenue growth [2][7]. - The report highlights the potential market space for key assets, estimating over USD 60 billion, with IBI363 alone contributing more than USD 40 billion. The company is also expected to introduce 8-10 new molecules annually from its innovation pipeline starting in 2026 [2][7]. Financial Forecast Changes - Revenue projections for 2025 have been revised down to RMB 12,505 million, a decrease of 37.1% from previous estimates. However, the 2026 revenue forecast has been increased by 26.7% to RMB 18,450 million, and the 2027 forecast has been raised by 18.6% to RMB 20,830 million [3]. - Gross profit for 2025 is now expected to be RMB 10,713 million, down 41.0% from prior estimates, while the gross profit margin is projected to be 85.7% [3]. - The net profit forecast for 2025 has been significantly reduced to RMB 1,055 million, reflecting an 87.9% decrease from previous estimates, but is expected to rise to RMB 3,502 million in 2026 and RMB 4,341 million in 2027 [3]. Stock Performance - The stock has shown a year-to-date increase of 17.57%, with a 52-week high of HKD 107.00 and a low of HKD 35.50, indicating strong market interest [6][12]. Valuation Model - The discounted cash flow (DCF) valuation model estimates the equity value at RMB 161,238 million, translating to a per-share value of HKD 105.00, based on projected free cash flows and a WACC of 9.9% [8][15].